OncoSec Medical Inc (ONCSQ)

[guti]

I am not talking about the combination study, I am only referring to the ImmunoPulse platform and its use of IL-12. The combination study obviously has more than one license involved, since Keytruda belongs to Merck and the study is being conducted and payed for by USCF, with the use of a Patent that belongs to the University of South Florida and the use of an electroporation device, which Oncosec owns the Patent for the specific voltage and outcome.